Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialResearch in context

Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trialResearch in context

Summary: Background: Compared with normal cells, tumour cells contain elevated levels of reactive oxygen species (ROS). Increased levels of the antioxidant protein NAD(P)H:quinone oxidoreductase 1 (NQO1) and phosphorylated signal transducer and activator of transcription 3 (pSTAT3) correlate negati...

Full description

Bibliographic Details
Main Authors: Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:EClinicalMedicine
Subjects:
Napabucasin
Pancreatic cancer
Adenocarcinoma
Metastatic pancreatic adenocarcinoma
Phosphorylated signal transducer and activator of transcription 3
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023000743

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023000743

Similar Items